Zobrazeno 1 - 10
of 1 423
pro vyhledávání: '"midostaurin"'
Publikováno v:
Journal of Blood Medicine, Vol Volume 15, Pp 421-433 (2024)
Douglas Tremblay,1 Nicole E Wagner,2 John Mascarenhas1 1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USACorrespondence: John Mascar
Externí odkaz:
https://doaj.org/article/f8731b288b4d4cb1a84923a97bc82925
Autor:
Weronika E. Borek, Luis Nobre, S. Federico Pedicona, Amy E. Campbell, Josie A. Christopher, Nazrath Nawaz, David N. Perkins, Pedro Moreno-Cardoso, Janet Kelsall, Harriet R. Ferguson, Bela Patel, Paolo Gallipoli, Andrea Arruda, Alex J. Ambinder, Andrew Thompson, Andrew Williamson, Gabriel Ghiaur, Mark D. Minden, John G. Gribben, David J. Britton, Pedro R. Cutillas, Arran D. Dokal
Publikováno v:
EBioMedicine, Vol 108, Iss , Pp 105316- (2024)
Summary: Background: Acute myeloid leukaemia (AML) is a bone marrow malignancy with poor prognosis. One of several treatments for AML is midostaurin combined with intensive chemotherapy (MIC), currently approved for FLT3 mutation-positive (FLT3-MP) A
Externí odkaz:
https://doaj.org/article/c1ed1c39383540cb899802e9a5af0c25
Autor:
Karam Ashouri, Krithika Chennapan, Anastasia Martynova, Samvel Nazaretyan, Amir Ali, Anush Aram Ginosyan, Eric Tam, Abdullah Ladha, Karrune Woan, Preet Chaudhary, Imran Siddiqi, George Yaghmour
Publikováno v:
eJHaem, Vol 5, Iss 2, Pp 423-427 (2024)
Externí odkaz:
https://doaj.org/article/275e3b98e2f440e8abd653b714c3971f
Autor:
Mohammed Alrouji, Sabina Yasmin, Fahad A Alhumaydhi, Sharaf E. Sharaf, Moyad Shahwan, Anas Shamsi
Publikováno v:
Frontiers in Chemistry, Vol 12 (2024)
Precision medicine has revolutionized modern cancer therapeutic management by targeting specific molecular aberrations responsible for the onset and progression of tumorigenesis. ROS proto-oncogene 1 (ROS1) is a receptor tyrosine kinase (RTK) that ca
Externí odkaz:
https://doaj.org/article/d67bd3815d2f42319eb6f1df1b1997d4
Autor:
D. I. Shikhbabaeva, O. Yu. Vinogradova, A. L. Neverova, M. M. Pankrashkina, M. V. Chernikov, E. O. Detkina, Yu. N. Kobzev, S. G. Malakho, V. V. Ptushkin
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 78-89 (2023)
Background. Mastocytosis is a heterogeneous group of diseases that are characterized by excessive proliferation and accumulation of clonal (neoplastic) mast cells in one or more organs. Advanced variants of systemic mastocytosis (aggressive systemic
Externí odkaz:
https://doaj.org/article/b0824ac883044800950c5541dea6c7c5
Autor:
Ji Eun Shin, Soo-Hyun Kim, Mingyu Kong, Hwa-Ryeon Kim, Sungmin Yoon, Kyung-Mi Kee, Jung Ah Kim, Dong Hyeon Kim, So Yeon Park, Jae Hyung Park, Hongtae Kim, Kyoung Tai No, Han-Woong Lee, Heon Yung Gee, Seunghee Hong, Kun-Liang Guan, Jae-Seok Roe, Hyunbeom Lee, Dong-Wook Kim, Hyun Woo Park
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-21 (2023)
Abstract Background Although the development of BCR::ABL1 tyrosine kinase inhibitors (TKIs) rendered chronic myeloid leukemia (CML) a manageable condition, acquisition of drug resistance during blast phase (BP) progression remains a critical challeng
Externí odkaz:
https://doaj.org/article/8eab8b0fc14041c7aad65f5279559725
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Blood and Lymphatic Cancer: Targets and Therapy, Vol Volume 12, Pp 137-147 (2022)
Amanda Blackmon,* Ibrahim Aldoss,* Brian J Ball* Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA*These authors contributed equally to this workCorrespondence: Bria
Externí odkaz:
https://doaj.org/article/08e1f1c8b0cb427b94f552bfa9160df0
Autor:
Meng-Ke Liu, Feng Liu, Yu-Ting Dai, Xiang-Qin Weng, Li-Li Cheng, Li-Quan Fan, Han Liu, Lu Jiang, Xiao-Jian Sun, Hai Fang, Li Wang, Wei-Li Zhao
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Mast cell leukemia is a rare and aggressive disease, predominantly with KIT D816V mutation. With poor response to conventional poly-chemotherapy, mast cell leukemia responded to the midostaurin treatment with a 50% overall response rate (ORR), but co
Externí odkaz:
https://doaj.org/article/7bccce04824d4586b259c41c50bfc365
Autor:
Scott Veitch, Deepti H. Radia
Publikováno v:
Diagnostics, Vol 14, Iss 1, p 80 (2023)
Advanced systemic mastocytosis (AdvSM) is a rare haematological neoplasm characterised by the accumulation of neoplastic mast cells (MCs) in various organs, resulting in organ dysfunction and reduced life expectancy. The subtypes include aggressive S
Externí odkaz:
https://doaj.org/article/eba8f905d8aa4b819e4aafd419d5f104